

Special Issue

Pulmonary Medicine: Diagnosis and Personalized Treatment

Message from the Guest Editor

Today, personalised medicine represents one of the most critical pillars for achieving disease prevention, early diagnosis and treatment. Its importance has become more evident in pulmonary medicine as well, with various examples observed in the clinical practice. The debate regarding genetic testing in interstitial lung diseases has been recently initiated, while targeted therapies have been increasingly used in severe asthma and chronic obstructive pulmonary disease (COPD). Despite this progress, there are still major challenges to confront in the near future, including lung toxicity and ethical issues. However, it is almost certain that through diverse tools (omics, pharmacogenetics, pharmacogenomics and sequencing technologies), researchers will manage to elucidate the molecular factors underlying the influence of genetic signatures on disease development and therapeutics. This Special Issue will focus on presenting recent advances in cutting-edge research regarding the identification of novel biomarkers, drug target discovery and novel therapeutics, as well as advances in technologies and resources in the field of respiratory diseases.


Guest Editor

Dr. Ioannis P. Tomos

5th Pulmonary Medicine Department, Sotiria Chest Diseases Hospital of Athens, 11527 Athens, Greece

Deadline for manuscript submissions

closed (10 May 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/175531

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

[jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).